For pediatric* and adult patients with primary humoral immunodeficiency
Proven. Personalized. Leader.
Proven: Efficacy & Tolerability
In addition to the US pivotal trial that confirmed the efficacy, safety, and tolerability of Hizentra, an extension study for an additional 1.7 years provided long-term data on this patient population.1,2
Hizentra has delivered safe and effective subcutaneous Ig (SCIg) since 2010 and has over 70,000 patient-years of experience.3 CSL Behring also offers IgIQ®, our support center for those involved with CSL Behring Ig therapy.